EZM0414 是一种有效、选择性、口服生物利用度高的SETD2抑制剂，在 SETD2 生化分析中，IC50值为18 nM；在细胞分析中，IC50值为34 nM。EZM0414可用于复发或难治性多发性骨髓瘤和弥漫性大 B 细胞淋巴瘤的研究。

EZM0414 is a potent, selective, orally bioavailable inhibitor of SETD2 with IC50 of 18 nM in SETD2 biochemical assay and IC50 of 34 nM in a cellular assay. EZM0414 can be used for the research of relapsed or refractory multiple myeloma and diffuse large B-cell lymphoma [1].

2411748-50-8

C22H29FN4O2

400.49

DMSO:115 mg/mL (287.15 mM),ultrasonic and warming and heat to 60°C
Powder: -20°C for 3 years
In solvent: -80°C for 2 years